Fate Therapeutics (FATE)
2.35
+0.02 (0.86%)
Upcoming Events
Latest Headlines
Fate Therapeutics to present FT819 CAR T-cell data at CCR-West
September 9, 2026 7:01 AM - StreetInsider
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
September 9, 2026 7:00 AM - StreetInsider
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
September 3, 2026 7:00 AM - StreetInsider
Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo
August 14, 2026 8:52 AM - StreetInsider
Fate Therapeutics (FATE) PT Raised to $8 at Piper Sandler
August 14, 2026 8:26 AM - StreetInsider
Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819
August 14, 2026 7:00 AM - StreetInsider
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
August 14, 2026 7:00 AM - StreetInsider
Form S-8 FATE THERAPEUTICS INC
August 13, 2026 4:08 PM - SEC Filing
Form 10-Q FATE THERAPEUTICS INC For: Jun 30
August 13, 2026 8:34 AM - SEC Filing
Form 8-K FATE THERAPEUTICS INC For: Aug 13
August 13, 2026 8:32 AM - SEC Filing
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 13, 2026 8:30 AM - StreetInsider
Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: TAHL CINDY
August 5, 2026 4:05 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: Valamehr Bahram
August 5, 2026 4:02 PM - SEC Filing
Form 144 FATE THERAPEUTICS INC Filed by: TAHL CINDY
August 4, 2026 4:40 PM - SEC Filing
Form 144 FATE THERAPEUTICS INC Filed by: Valamehr Bahram
August 4, 2026 4:35 PM - SEC Filing
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026 4:05 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)
July 10, 2026 6:52 AM - StreetInsider
Fate Therapeutics gets FDA clearance for FT839 CAR T-cell candidate
July 9, 2026 8:30 AM - StreetInsider
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
July 9, 2026 8:30 AM - StreetInsider
Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
July 8, 2026 11:13 AM - SEC Filing
Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR
July 6, 2026 8:31 AM - StreetInsider
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
July 6, 2026 8:30 AM - StreetInsider
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
July 1, 2026 4:05 PM - Globe NewsWire
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Redmile Group, LLC
June 15, 2026 5:17 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Lee Michael Stewart
June 15, 2026 5:16 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Xu Yuan
June 15, 2026 4:10 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Jooss Karin
June 15, 2026 4:10 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: EPSTEIN ROBERT S
June 15, 2026 4:09 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Agarwal Shefali
June 15, 2026 4:08 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: ABERNETHY MATT
June 15, 2026 4:07 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: RASTETTER WILLIAM H
June 15, 2026 4:06 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Hamill Laura
June 15, 2026 4:05 PM - SEC Filing
Form 3 FATE THERAPEUTICS INC For: Jun 12 Filed by: Hamill Laura
June 15, 2026 4:04 PM - SEC Filing
Form 8-K FATE THERAPEUTICS INC For: Jun 12
June 15, 2026 4:03 PM - SEC Filing
Fate Therapeutics appoints Laura Hamill to board of directors
June 15, 2026 8:30 AM - StreetInsider
Fate Therapeutics Appoints Laura Hamill to Board of Directors
June 15, 2026 8:30 AM - StreetInsider
Full Article List
